Evidence map›Paper›PMID 37237294›Full record

ArticleJournal of nanobiotechnology2023

Bioengineered stem cell membrane functionalized nanoparticles combine anti-inflammatory and antimicrobial properties for sepsis treatment.

Lu Lu, Lingli Quan, Jian Li, Junbin Yuan, Xinmin Nie, Xueyuan Huang, Hang Dong, Yanrong Su, Yufen Huang, Qingjie Kou and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Lu LuDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Lingli QuanDepartment of Pulmonary and Critical Care Medicine, The Affiliated Zhuzhou Hospital of Xiangya Medical College, Central South University, Zhuzhou, 412007, China.
Jian LiDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Junbin YuanDepartment of Urology, The Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Xinmin NieDepartment of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Xueyuan HuangDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Hang DongDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Yanrong SuDepartment of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Yufen HuangDepartment of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Qingjie KouDepartment of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Leping LiuDepartment of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Haiting LiuDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Xionghui ZhouDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Rong GuiDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China. guirong@csu.edu.cn.
Lan GuDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China. gulan0604@csu.edu.cn.
Third Xiangya Hospital · CNCentral South University · CN

Funding

National Natural Science Foundation of China 82002098Natural Science Foundation of Hunan province in China 2021JJ31001Postgraduate Research and Innovation Project of Central South University 2021zzts1093, 2021zzts1084, 2022zzts0890Wisdom Accumulation and Talent Cultivation Project of the Third xiangya hospital of Central South University BJ202101
6 · The paper itself

Abstract

backgroundSepsis is a syndrome of physiological, pathological and biochemical abnormalities caused by infection. Although the mortality rate is lower than before, many survivors have persistent infection, which means sepsis calls for new treatment. After infection, inflammatory mediators were largely released into the blood, leading to multiple organ dysfunction. Therefore, anti-infection and anti-inflammation are critical issues in sepsis management.

resultsHere, we successfully constructed a novel nanometer drug loading system for sepsis management, FZ/MER-AgMOF@Bm. The nanoparticles were modified with LPS-treated bone marrow mesenchymal stem cell (BMSC) membrane, and silver metal organic framework (AgMOF) was used as the nanocore for loading FPS-ZM1 and meropenem which was delivery to the infectious microenvironments (IMEs) to exert dual anti-inflammatory and antibacterial effects. FZ/MER-AgMOF@Bm effectively alleviated excessive inflammatory response and eliminated bacteria. FZ/MER-AgMOF@Bm also played an anti-inflammatory role by promoting the polarization of macrophages to M2. When sepsis induced by cecal ligation and puncture (CLP) challenged mice was treated, FZ/MER-AgMOF@Bm could not only reduce the levels of pro-inflammatory factors and lung injury, but also help to improve hypothermia caused by septic shock and prolong survival time.

conclusionsTogether, the nanoparticles played a role in combined anti-inflammatory and antimicrobial properties, alleviating cytokine storm and protecting vital organ functions, could be a potential new strategy for sepsis management.

Indexed as

NanoparticlesSepsisAnimalsAnti-Bacterial AgentsCell MembraneDisease Models, AnimalMacrophagesMiceAnti-Bacterial AgentsAntibacterialCytokine stormMesenchymal stem cellsMetal-organic frameworksepsis

Identifiers

PMID37237294
PMCPMC10214628
OpenAlexW4378378443

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.